---
title: "New-onset type 2 diabetes mellitus and risk of obesity-related cancers: UK Biobank matched cohort"
id: "medrxiv-3-new-onset-type-2-diabetes-mellitus-and-obesity-related-cancer-risk-a-matched"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-3-new-onset-type-2-diabetes-mellitus-and-obesity-related-cancer-risk-a-matched"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1?rss=1"
published_at: "2026-08-27T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# New-onset type 2 diabetes mellitus and risk of obesity-related cancers: UK Biobank matched cohort
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-3-new-onset-type-2-diabetes-mellitus-and-obesity-related-cancer-risk-a-matched
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1?rss=1)
- **Published At:** 2026-08-27T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This UK Biobank matched cohort study compared 23,771 participants with **new-onset type 2 diabetes mellitus (T2DM)** to 71,170 unexposed participants matched 1:3 on **BMI**, age, and sex using a sequential longitudinal approach. - The study aimed to estimate BMI-independent, causal associations between new-onset T2DM and incident cancer while minimising confounding, immortal time bias, and detection-time bias. - Primary outcomes were total incident cancer, split into **obesity-related cancers (ORCs)** and non-obesity-related cancers (NORCs); secondary outcomes were site-specific cancers. - Median follow-up was 5 years; there were 7,694 incident cancers (T2DM: 2,432; unexposed: 5,262). - Time-split Cox models produced time-split hazard ratios (tsHRs) with 95% confidence intervals stratified by sex to assess effects over time. - In men, new-onset T2DM was associated with higher incidence of **obesity-related cancers** (tsHR 1.39, 95% CI 1.21–1.59). Stronger site-specific effects were seen for **hepatocellular carcinoma** (tsHR 3.97, 95% CI 2.38–6.65), **pancreatic cancer** (tsHR 1.77, 95% CI 1.15–2.72), and **kidney cancer** (tsHR 1.62, 95% CI 1.13–2.32). - In women, there was evidence for an effect of new-onset T2DM on **obesity-related cancers** (tsHR 1.33, 95% CI 1.16–1.52), but the specific contributing cancer types were less clearly defined in the report. - There were no observed associations between new-onset T2DM and **post-menopausal breast cancer** or **endometrial cancer**, despite these two cancers' well-established links with elevated BMI. - No effect of new-onset T2DM was found on incidence of NORCs. - The authors report evidence of **detection-time bias**, particularly in men, and emphasise that this is the first large-scale study to present evidence for BMI-independent associations between new-onset T2DM and incident cancer. - Funding sources included Cancer Research UK and other research councils; ethical approvals and participant consent were confirmed. Data access is via UK Biobank application.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=jfe7UTQrNIu.khELY9hgYe6kflm_q9q0PA2LJHlHaMo-1787881509.4576962-1.2.1.1-K3im1N_YtdzuA0aoU.fj_MdjIwDiZpmk5aDR4IzIkD7cZEcqsn42OcqXJq1sZ41V) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # New-onset type 2 diabetes mellitus and obesity-related cancer risk: a matched cohort study (UK Biobank) [ View ORCID Profile](http://orcid.org/0009-0000-2280-8279)Owen Tipping, [ View ORCID Profile](http://orcid.org/0000-0001-7591-522X)Mengying Wang, Richard Martin, [ View ORCID Profile](http://orcid.org/0000-0002-5351-9960)Matthew Sperrin, [ View ORCID Profile](http://orcid.org/0000-0002-9115-4405)Andrew Renehan doi: https://doi.org/10.64898/2026.08.25.26360729 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Owen Tipping 1 University of Manchester; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Owen%2BTipping%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tipping%20O&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AOwen%2BTipping%2B) * [ORCID record for Owen Tipping](http://orcid.org/0009-0000-2280-8279 "Open in new tab") Mengying Wang 1 University of Manchester; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mengying%2BWang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wang%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMengying%2BWang%2B) * [ORCID record for Mengying Wang](http://orcid.org/0000-0001-7591-522X "Open in new tab") Richard Martin 2 University of Bristol; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richard%2BMartin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Martin%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARichard%2BMartin%2B) Matthew Sperrin 3 The University of Manchester * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Matthew%2BSperrin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sperrin%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMatthew%2BSperrin%2B) * [ORCID record for Matthew Sperrin](http://orcid.org/0000-0002-5351-9960 "Open in new tab") Andrew Renehan 1 University of Manchester; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrew%2BRenehan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Renehan%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrew%2BRenehan%2B) * [ORCID record for Andrew Renehan](http://orcid.org/0000-0002-9115-4405 "Open in new tab") * For correspondence: andrew.renehan@manchester.ac.uk * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1287482/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1287482/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1287482/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1287482/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1287482/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1287482/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Observational research reports positive associations between type 2 diabetes mellitus (T2DM) and obesity-related cancers (ORCs), but causality remains unclear due to confounding (namely the shared risk factor of obesity, commonly approximated as body mass index, BMI), immortal time bias, and detection-time bias. Here, we aimed to use causal inference methods to minimise the above problems and estimate causal associations between new-onset T2DM and incident cancer. Methods: We performed a cohort study within UK Biobank, comparing new-onset T2DM with unexposed individuals matched 1 to 3 on BMI, age, and sex using a sequential longitudinal approach. The primary outcomes were total incident cancer, divided into ORCs and non-obesity-related cancers (NORCs). The secondary outcomes were site-specific cancers. We developed Cox models to estimate time-split hazard ratios (tsHRs) and 95% confidence intervals (CIs) stratified by sex. Findings: 23,771 participants with new-onset T2DM were matched with 71,170 unexposed participants. During a median follow-up of 5 years, there were 7694 (T2DM: 2432; unexposed: 5262) incident cancers. In men, there was evidence for an effect of T2DM on obesity-related cancer (tsHR 1.39, 95% CI 1.21-1.59), particularly on hepatocellular carcinoma (tsHR 3.97, 95% CI 2.38-6.65), pancreatic (tsHR 1.77, 95% CI 1.15-2.72) and kidney (tsHR 1.62, 95% CI 1.13-2.32) cancers. In women, there was evidence for an effect on obesity-related cancers (tsHR 1.33, 95% CI 1.16-1.52). Importantly, there were no associations with post-menopausal breast and endometrial cancers, two cancer types consistently associated with elevated BMI. There was no effect of new-onset T2DM on incidence of NORCs. There was evidence of detection-time bias, particularly in men. Interpretation: This is the first large-scale study to demonstrate evidence of a BMI-independent associations between new-onset T2DM and incident cancer. In men, this was primarily driven by hepatocellular carcinoma, pancreatic cancer, and kidney cancer. In women, the underlying cancers driving this relationship were less clearly defined. Funding: This study was funded by Cancer Research UK and administered through the Manchester Cancer Research Centre MB-PhD scheme (SEBCATP-2023/100010). ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Researchers can apply to use the UK Biobank resource and access all data used within this study. ## Funder Information Declared : Cancer Research UK, NIHR202411 UKRI AI programme, and the Engineering and Physical Sciences Research council, for CHAI – Causality in Healthcare AI Hub, EP/Y028856/1 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.24.26361257v1 "Potential Cost of Multi-Cancer Detection Tests to Medicare")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.21.26360249v1 "A Framework For Large-Scale Reconstruction Of Extended Pedigrees To Facilitate Gene Discovery In ALS") Posted August 27, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/27/2026.08.25.26360729.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.25.26360729v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/27/2026.08.25.26360729.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) New-onset type 2 diabetes mellitus and obesity-related cancer risk: a matched cohort study (UK Biobank) Owen Tipping, Mengying Wang, Richard Martin, Matthew Sperrin, Andrew Renehan medRxiv 2026.08.25.26360729; doi: https://doi.org/10.64898/2026.08.25.26360729 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26360729v1%26text%3DNew-onset%2520type%25202%2520diabetes%2520mellitus%2520and%2520obesity-related%2520cancer%2520risk%253A%2520a%2520matched%2520cohort%2520study%2520%2528UK%2520Biobank%2529 "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26360729v1%26t%3DNew-onset%2520type%25202%2520diabetes%2520mellitus%2520and%2520obesity-related%2520cancer%2520risk%253A%2520a%2520matched%2520cohort%2520study%2520%2528UK%2520Biobank%2529 "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26360729v1%26title%3DNew-onset%2520type%25202%2520diabetes%2520mellitus%2520and%2520obesity-related%2520cancer%2520risk%253A%2520a%2520matched%2520cohort%2520study%2520%2528UK%2520Biobank%2529%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26360729v1%26title%3DNew-onset%2520type%25202%2520diabetes%2520mellitus%2520and%2520obesity-related%2520cancer%2520risk%253A%2520a%2520matched%2520cohort%2520study%2520%2528UK%2520Biobank%2529 "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.25.26360729) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.25.26360729v1&count=horizontal&via=&text=New-onset%20type%202%20diabetes%20mellitus%20and%20obesity-related%20cancer%20risk%3A%20a%20matched%20cohort%20study%20%28UK%20Biobank%29&counturl=www.medrxiv.org/content/10.64898/2026.08.25.26360729v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (612) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (892) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (325) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4753) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (640) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1610) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15803) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6969) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (726) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1051) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4959) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1422) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1731) * [Hematology](https://www.medrxiv.org/collection/hematology) (578) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1329) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16227) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1158) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (661) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (718) * [Neurology](https://www.medrxiv.org/collection/neurology) (7161) * [Nursing](https://www.medrxiv.org/collection/nursing) (360) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1072) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1226) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (998) * [Oncology](https://www.medrxiv.org/collection/oncology) (3563) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1032) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (392) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (445) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (464) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (702) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1770) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (730) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (758) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5813) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9665) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2371) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1428) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1236) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (632) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (762) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (572) * [Surgery](https://www.medrxiv.org/collection/surgery) (762) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (106) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (301) * [Urology](https://www.medrxiv.org/collection/urology) (285) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP m
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [GLP-1 medications and temporary hair loss risk in type 2 diabetes](https://medichelpline.com/clinical-feed/medical-news-today-0-glp-1-drugs-linked-to-temporary-hair-loss-here-s-why.md)
- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- [Konstantinos Stefanakis: Blood-based Proteomics to Detect MASLD/MASH — ENDO 2026 Audience Choice](https://medichelpline.com/clinical-feed/endocrine-news-0-star-power-2026-q-a-with-konstantinos-stefanakis-md.md)
- [Exercise Modalities for Adults with Type 2 Diabetes and Obesity: Comparative Effects on Visceral F](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-exercise-modalities-for-adults-with-type-2-diabetes-mellitus-and-obesity.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.